| # | Title | Journal | Year | Citations |
|---|
| 1 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | Annals of Oncology | 2019 | 329 |
| 2 | Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) | Oncologist | 2012 | 170 |
| 3 | Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer | JAMA Oncology | 2021 | 92 |
| 4 | Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma | Journal of Thoracic Oncology | 2020 | 84 |
| 5 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium | Journal of Clinical Oncology | 2021 | 83 |
| 6 | A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study | European Urology | 2014 | 39 |
| 7 | Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy | Annals of Oncology | 2010 | 38 |
| 8 | Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial | International Journal of Radiation Oncology Biology Physics | 2016 | 28 |
| 9 | Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project | Annals of Oncology | 2015 | 25 |
| 10 | Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy | JAMA Oncology | 2019 | 25 |
| 11 | Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility | Modern Pathology | 2018 | 24 |
| 12 | A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours | European Journal of Cancer | 1994 | 22 |
| 13 | Abiraterone Acetate Withdrawal Syndrome: Does It Exist? | Case Reports in Oncology | 2012 | 21 |
| 14 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials | Clinical Cancer Research | 2022 | 21 |
| 15 | Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder | Radiotherapy and Oncology | 2021 | 19 |
| 16 | Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial | Clinical Cancer Research | 2018 | 15 |
| 17 | Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? | European Journal of Cancer | 2016 | 12 |
| 18 | Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group | Clinical Genitourinary Cancer | 2020 | 12 |
| 19 | Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). | Journal of Clinical Oncology | 2016 | 12 |
| 20 | High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study | British Journal of Cancer | 2001 | 6 |
| 21 | Primary Adenocarcinoma of the Seminal Vesicle | Rare Tumors | 2017 | 6 |
| 22 | Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. | Journal of Clinical Oncology | 2017 | 6 |
| 23 | Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial. | Journal of Clinical Oncology | 2017 | 6 |
| 24 | Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study | Bone Marrow Transplantation | 2006 | 4 |
| 25 | Neoadjuvant chemotherapy in muscle-invasive bladder cancer: Ready for prime time? | Critical Reviews in Oncology/Hematology | 2013 | 4 |
| 26 | Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization | Translational Andrology and Urology | 2018 | 4 |
| 27 | Breast cancer in patients under 18 years. Report of an inflammatory case and review of the literature | Breast | 1996 | 2 |
| 28 | Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer. | Journal of Clinical Oncology | 2015 | 2 |
| 29 | Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer | European Journal of Cancer | 2018 | 1 |
| 30 | Results of the GETUG-AFU 19 trial: A randomized phase II study of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) with or without anti-epidermal growth factor receptor (EGF-R) monoclonal antibody panitumumab (PANI) in advanced transitional cell carcinoma (ATCC). | Journal of Clinical Oncology | 2017 | 1 |
| 31 | Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step | European Urology | 2018 | 0 |
| 32 | Reducing the burden of chemotherapy in stage IIB/C testicular seminoma | Current Problems in Cancer Case Reports | 2020 | 0 |
| 33 | Chemotherapy for Elderly Patients with Advanced Transitional Cell Carcinoma | | 2013 | 0 |
| 34 | A comparison of the outcomes after neoadjuvant (NC) or adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French contemporary retrospective multicenter cohort. | Journal of Clinical Oncology | 2015 | 0 |
| 35 | Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program. | Journal of Clinical Oncology | 2015 | 0 |
| 36 | Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C). | Journal of Clinical Oncology | 2015 | 0 |
| 37 | Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC). | Journal of Clinical Oncology | 2015 | 0 |
| 38 | Management of metastatic prostate cancer patients in first line: Audit of real-life practices. | Journal of Clinical Oncology | 2016 | 0 |
